尿液上清液揭示可预测透明细胞肾细胞癌生存的特征
本研究前瞻性收集小队列透明细胞肾细胞癌(ccRCC)患者的无细胞尿液上清液和血浆,用多重邻位延伸分析法检测92种炎症相关蛋白浓度,并结合癌症基因组图谱(TCGA)数据对编码上述蛋白的基因进行靶向mRNA分析,明确其对总生存期(OS)的影响。无监督聚类分析显示ccRCC患者无细胞尿液上清液存在炎症特征,利用TCGA数据通过向后逐步回归确定转录组风险因素并构建预测2年和5年OS的列线图,决策曲线分析显示该模型较全治疗/不治疗策略有净获益改善。作者定义四种新型生物标志物,并认为该分析若未来得到验证,可提供非侵入性预后信息。
要点
- 无监督聚类分析显示ccRCC患者无细胞尿液上清液存在炎症特征。
- 利用TCGA数据通过向后逐步回归确定转录组风险因素并构建预测2年和5年OS的列线图。
- 决策曲线分析显示该模型较全治疗/不治疗策略有净获益改善。
核心结论
- 作者利用蛋白质组和转录组数据定义了四种新型生物标志物,可区分ccRCC预后严重程度。
- 作者表明这些生物标志物可用于模型预测不同肿瘤分期的ccRCC的2年和5年OS。
- 作者认为该分析若未来得到验证,可提供非侵入性预后信息,可能为患者的管理或监测策略提供信息。
研究设计与样本
- 前瞻性收集小队列ccRCC患者样本,用多重邻位延伸分析法检测无细胞尿液上清液和血浆中92种炎症相关蛋白浓度。
- 从TCGA获取ccRCC患者转录组和临床信息,对编码显著差异表达蛋白的基因进行靶向mRNA分析。
- 对蛋白浓度数据进行无监督聚类和差异蛋白表达分析,用向后逐步回归构建列线图,并通过区分度、校准和决策曲线分析评估列线图性能和临床获益。
主要发现
- 无监督聚类分析显示ccRCC患者无细胞尿液上清液存在炎症特征。
- 利用TCGA数据的向后逐步回归确定了与OS相关的转录组风险因素和风险组。
- 利用这些风险因素构建了预测2年和5年OS的列线图。
- 决策曲线分析显示该模型较全治疗/不治疗策略有净获益改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To profile the cell-free urine supernatant and plasma of a small cohort of clear-cell renal cell carcinoma (ccRCC) patients by measuring the relative concentrations of 92 proteins related to inflammation. Using The Cancer Genome Atlas (TCGA), we then performed a targeted mRNA analysis of genes encoding the above proteins and defined their effects on overall survival (OS). SUBJECTS/PATIENTS AND METHODS: Samples were collected prospectively from ccRCC patients. A multiplex proximity extension assay was used to measure the concentrations of 92 inflammation-related proteins in cell-free urine supernatants and plasma. Transcriptomic and clinical information from ccRCC patients was obtained from TCGA. Unsupervised clustering and differential protein expression analyses were performed on protein concentration data. Targeted mRNA analysis on genes encoding significant differentially expressed proteins was performed using TCGA. Backward stepwise regression analyses were used to build a nomogram. The performance of the nomogram and clinical benefit was assessed by discrimination and calibration, and a decision curve analysis, respectively. RESULTS: Unsupervised clustering analysis revealed inflammatory signatures in the cell-free urine supernatant of ccRCC patients. Backward stepwise regressions using TCGA data identified transcriptomic risk factors and risk groups associated with OS. A nomogram to predict 2-year and 5-year OS was developed using these risk factors. The decision curve analysis showed that our model was associated with a net benefit improvement compared to the treat-all/none strategies. CONCLUSION: We defined four novel biomarkers using proteomic and transcriptomic data that distinguish severity of prognosis in ccRCC. We showed that these biomarkers can be used in a model to predict 2-year and 5-year OS in ccRCC across different tumour stages. This type of analysis, if validated in the future, provides non-invasive prognostic information that could inform either management or surveillance strategies for patients.
引用
- Daza J, Salomé B, Okhawere K, et al. Urine supernatant reveals a signature that predicts survival in clear-cell renal cell carcinoma. BJU Int. 2023. PMID: 36797809. doi:10.1111/bju.15989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。